These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15472801)

  • 1. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect.
    Alkan Y; Haefeli WE; Burhenne J; Stein J; Yaniv I; Shalit I
    Clin Infect Dis; 2004 Sep; 39(6):e49-52. PubMed ID: 15472801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torsades de pointes associated with voriconazole use.
    Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR
    Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
    Elbey MA; Cil H; Onturk E; Islamoglu Y
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole-induced QT interval prolongation and torsades de pointes.
    Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
    Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
    [No Abstract]   [Full Text] [Related]  

  • 5. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
    Tatetsu H; Asou N; Nakamura M; Hanaoka N; Matsuno F; Horikawa K; Mitsuya H
    Am J Hematol; 2006 May; 81(5):366-9. PubMed ID: 16628725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole-induced bradycardia without QT interval prolongation: a possible non-concentration-dependent adverse effect.
    Perbet S; Blondonnet R; Guérin R; Cayot-Constantin S; Constantin JM
    Intensive Care Med; 2013 Mar; 39(3):531-2. PubMed ID: 23291731
    [No Abstract]   [Full Text] [Related]  

  • 7. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
    Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
    J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole-associated myositis.
    Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
    J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment with voriconazole for disseminated cutaneous and visceral infection by Fusarium solani in a patient with acute myeloid leukemia].
    Muramatsu T; Ueki T; Ohashi K; Negishi K; Suzuki T; Shitara M; Honma M; Ito T; Sakai M; Yamashita T; Akiyama H; Sakamaki H
    Rinsho Ketsueki; 2006 Aug; 47(8):753-7. PubMed ID: 16986714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole.
    Tsubokura M; Miura Y; Itokawa T; Murata K; Takei N; Higaki T; Murashige N; Kami M; Komatsu T
    J Clin Pharmacol; 2011 Oct; 51(10):1488-90. PubMed ID: 21098688
    [No Abstract]   [Full Text] [Related]  

  • 11. Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients.
    Conlon JD; Dauenhauer M; Tonkovic-Capin V; Talano J; Margolis D; Drolet BA; Fairley JA
    J Am Acad Dermatol; 2008 Mar; 58(3):484-7. PubMed ID: 18280346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
    Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole induced bradycardia.
    Uludağ D; Ozdemir N; Tüysüz G; Eroğlu AG; Celkan T
    Pediatr Hematol Oncol; 2013 Oct; 30(7):674-6. PubMed ID: 23484777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole-induced photosensitivity.
    Malani AN; Aronoff DM
    Clin Med Res; 2008 Sep; 6(2):83-5. PubMed ID: 18801950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
    Zeuli JD; Wilson JW; Estes LL
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe phototoxicity associated with long-term voriconazole treatment.
    Vöhringer S; Schrum J; Ott H; Höger PH
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):274-6. PubMed ID: 21050383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl.
    Racette AJ; Roenigk HH; Hansen R; Mendelson D; Park A
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S81-5. PubMed ID: 15858516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
    Frick MA; Soler-Palacín P; Martín Nalda A; Guarner ME; Nadal CF
    Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.